Rocket Lab USA, Inc.

Executive Summary

HOLD, Low conviction. RKLB rates a HOLD at Low conviction. The business is executing better on revenue, backlog, and EBITDA than it was two years ago, but the stock still prices in a successful Neutron ramp and durable Space Systems growth before either has translated into earnings or free cash flow. After a -50.98% three-month reset and with shares -51.9% off the high, the setup is less dangerous than it was, but valuation remains the problem, not the story.

Investment Thesis

Rocket Lab has graduated from a niche launch story into a broader space infrastructure and defense company. That matters. The operating facts are much better than they were two years ago: Q2 2026 revenue hit $234M, up 62% y/y; adjusted EBITDA loss narrowed to -$8.8M; backlog reached $2.36B; and the company signed over $1B of contracts in and after the quarter. Electron is still executing with 13 launches YTD and 100% mission success, while Space Systems is proving it can absorb larger manufacturing programs and government work. This is not a broken company.

The problem is price, not progress. At $72.57, investors are paying 59.41x sales for a company that still posted FY2025 operating margin of -44.2%, net margin of -44.3%, and FCF of -$0.1B. That multiple only makes sense if Neutron becomes a successful medium-lift platform on a commercially attractive curve, and if the broader platform then compounds into much higher earnings power over several years. That may happen, but the stock is asking investors to underwrite it before the evidence exists. Q3 guidance itself shows the tension: revenue should rise to $250M-$265M, but adjusted EBITDA loss is expected to widen to -$17M to -$23M because Neutron spend is still heavy.

The case now depends on three things. First, Neutron has to move from slideware and schedule talk to real hardware milestones, with the current benchmark being Q4 2026 pad delivery after the old mid-2025 launch target slipped. Second, Space Systems must keep converting backlog into revenue without gross margin collapsing under mix shift and Mynaric integration drag, especially with Q3 GAAP gross margin guided down to 29%-31% from 36.1% in Q2. Third, management needs to turn a mixed reporting record into a cleaner one. The company has beaten some key EBITDA targets, but it has also missed EPS in 5 of the last 8 quarters, which matters when the market already gives it a hero multiple.

The stock is also in a different place technically than it was at the highs. Shares are -51.9% below the $151 peak and -7.8% below the 200-day average, so some excess optimism has already been wrung out. That lowers near-term downside from pure momentum air pockets. It does not create valuation support by itself. Until Neutron de-risks materially or earnings power catches up faster than expected, the right stance is to respect the company and resist the stock.

Key Metrics

Financial Strength

The balance sheet is the strongest part of the risk profile. Rocket Lab has very low leverage at 0.04 debt/equity, a 5.48 current ratio, and roughly $2.4B of liquidity after raising $1.08B through an ATM. That gives the company time to absorb negative free cash flow and elevated Neutron spending without immediate financing stress. The weak point is not solvency but economic conversion: margins are still deeply negative on a full-year basis, free cash flow remains negative, and Q3 margin guidance steps down even as revenue rises, which shows this is still a scale-and-invest story rather than a self-funding one.

Competitive Position

Rocket Lab's moat is built on a hard-to-replicate stack: proven small-launch operations, vertically integrated spacecraft production, defense credibility, and a growing installed customer base that feeds repeat business. The durability is real in Electron and Space Systems, where flight heritage and manufacturing know-how matter, but the biggest moat expansion still depends on Neutron becoming a reliable medium-lift platform. Until that happens, the moat is good, not impregnable.

Management & Guidance

Current guidance is for Q3 2026 revenue of $250M-$265M, GAAP gross margin of 29%-31%, non-GAAP gross margin of 35%-37%, GAAP operating expenses of $143M-$149M, and an adjusted EBITDA loss of $17M-$23M. That is a credible near-term outlook because Q2 execution was better than guided, especially on EBITDA and gross margin. The credibility discount comes from timing, not demand: management has built backlog and scaled revenue, but Neutron has moved from a mid-2025 first-launch target in the 2024 Q3 call to a Q4 2026 pad-delivery target with a narrowing launch window. Near-term revenue guidance deserves respect. Long-dated schedule promises deserve a haircut.

Segment Analysis

• Space Systems (Not disclosed in provided data): The main Q2 2026 growth driver, supported by satellite manufacturing, Flatellite and GEO awards, Mynaric contribution, and $581M of contracts signed in Q2 and post-quarter.
• Launch (Not disclosed in provided data): Electron remains active with 13 launches YTD and 100% mission success; launch bookings totaled $437M in Q2 and post-quarter, including a $266M Space Force award. Neutron is the largest future value driver.
• Geography (Not disclosed in provided data): Revenue mix by geography was not provided, but recent contract flow points to meaningful U.S. government and defense exposure.

Capital Allocation

Capital allocation is aggressive but rational for a company still in platform-build mode. Free cash flow is -$0.1B, capex stays elevated with Neutron and launch-site infrastructure, and management used a $1.08B ATM to push liquidity to about $2.4B, explicitly preserving capacity for Iridium-related work and broader M&A. There are no buybacks and no dividend, which is appropriate given the current stage, but dilution is the trade-off shareholders are funding.

Management Execution & Track Record

Management has improved the business meaningfully since the 2024 Q3 call, but not all promises landed on time. The good: revenue scaled from $105M in 2024 Q3 to $234M in 2026 Q2, backlog grew from $1.05B to $2.36B, and adjusted EBITDA margin improved from -29.4% then to -9.6% now, despite ongoing Neutron spend. The miss: in late 2024 management still pointed to a mid-2025 Neutron first launch and a cadence of 1 launch in 2025, 3 in 2026, 5 in 2027; by the 2026 Q2 call, management had shifted to Q4 2026 pad delivery with the end-year launch window narrowing. Guidance credibility is mixed rather than poor: Rocket Lab beat EBITDA guidance decisively in Q2 2026, but the earnings track record shows 5 misses in the last 8 quarters, including the latest -37.2% EPS miss. Net read: credible builders, not yet clean enough forecasters to deserve a near-60x sales multiple without discount.

Positioning & Flows

Ownership is institutionally supported but not crowded in a way that guarantees downside protection. The top three institutions hold 41.4%, insiders own 5.2%, and short interest is 8.50% of shares outstanding, or 45.8M shares with only 1.7 days-to-cover, enough for volatility but not a classic squeeze setup. Options positioning shows a negative gamma regime with zero-gamma at $75.08, slightly above spot, which can amplify moves around earnings but does not change the fundamental valuation debate.

Bull Case

• Launch and Space Systems are both scaling: Q2 2026 revenue of $234M grew 62% y/y, helped by satellite manufacturing and Mynaric, and management expects another 10% q/q step-up in Q3.
• Execution improved sharply at the EBITDA line: Q2 adjusted EBITDA loss was -$8.8M versus guidance for -$20M to -$26M, and EBITDA margin improved 570 bps q/q and 2,660 bps y/y to -9.6%.
• Demand is not the issue: backlog sits at $2.36B, launch bookings added $437M, Space Systems signed $581M, and the company won a record $266M Space Force award.
• Balance sheet risk is low for now: debt/equity is just 0.04, current ratio is 5.48, and liquidity is about $2.4B after $1.08B of ATM proceeds, which buys time to finish Neutron and fund M&A.

Bear Case

• Valuation is extreme: RKLB trades at 59.41x sales against a 4.0x peer average, while the quant engine's target is $64.42, or -11.2% from the current $72.57.
• Profitability is still distant: FY2025 EPS was -$0.37, operating margin was -44.2%, net margin -44.3%, and Q3 2026 guidance still calls for an adjusted EBITDA loss of $17M-$23M.
• Neutron timing has slipped materially: in the 2024 Q3 call, management still targeted a mid-2025 first launch; now the vehicle is only expected at the pad in Q4 2026, and management says the end-year first-launch window is narrowing.
• Execution is not clean enough to underwrite a premium this large: earnings misses occurred in 5 of the last 8 reported quarters, including the latest -37.2% EPS miss on 2026-08-10.

Valuation & Price Target

Engine price target $64.42 (-11.2% vs current), Low confidence.

• P/S Multiple: $3.57 (5% weight)
• Quality-adjusted: $80.7 (20% weight)

The rating stays aligned with the quant baseline at HOLD, and the reason is straightforward: the business quality is better than the valuation screen suggests, but not enough better to overcome 59.41x sales, a Low confidence engine target of $64.42, and a peer set with wide dispersion of 5.9x on P/E that weakens comp-based upside arguments. The balance sheet is stronger than a typical pre-profit company, with debt/equity at 0.04 and liquidity near $2.4B, and the operating trajectory is clearly better with Q2 revenue up 62% y/y and EBITDA loss at -$8.8M. That keeps the call from turning bearish. But the latest quarter also came with a -37.2% EPS miss, Q3 EBITDA guidance back to -$17M to -$23M, and Neutron still not flying after the prior mid-2025 target. Sell-side consensus remains Strong Buy with 11 buy / 1 hold / 0 sell, but that is low-signal context here, not a reason to ignore the valuation gap.

Risk Assessment

Risk score 46/100 (Moderate). The biggest risk is that Neutron slips again from the current Q4 2026 pad-delivery target, because a stock at 59.41x sales is implicitly capitalizing medium-lift success well before it exists in the field.

The Bottom Line

RKLB rates a HOLD with Low conviction. The company is winning business, scaling revenue, and carrying enough liquidity to keep building, which makes a simple bearish call too blunt. But the stock still asks investors to pay for a future medium-lift franchise that has not flown, at 59.41x sales and with losses still firmly in place. A shift to BUY would require either a much lower entry price or hard Neutron de-risking with cleaner margin conversion. A shift to SELL would require another meaningful Neutron slip or evidence that backlog growth is not translating into durable economics.